watsonhelper • For what it's worth.I have not
Post# of 30028
Posted On: 09/04/2014 10:37:11 AM
watsonhelper •
For what it's worth.I have not heard detail in quite some time and just spent time with key players not at Amarantus. Sounds like two critical things happen this month and one next month. Take it for what it's worth, I already know several will bash and also use their aliases to smear me. For the others:
(submissions to the FDA are not always public, companies choose to not let people down if the FDA denies it, until they are ready to let people down), both of these IND will be approved, there is no question based on unmet need.
-MANF approved for one ORPH IND end of SEPT (RP suspect)
-MANF approved for one ORPH IND end of OCT (Wolframs suspect)
-Lympro licensing partnership in Sept, diagnostic, not pharma, still just as huge if the diagnostic retains exclusivity in the US.
Just strong opinions from people far more in the know. Most of this makes sense and shouldn't be a huge surprise to anyone. Hopefully everyone's targets are hit and this can do what it was meant to do for people. Best of luck
PS, the Lympro aspect would make shares and RS unnecessary, by voting for both on your proxy, you're giving AMBS power to negotiate. Remember that the BOD and Gerald make these decisions, not just Gerald, so look at your BOD before slamming GC
For what it's worth.I have not heard detail in quite some time and just spent time with key players not at Amarantus. Sounds like two critical things happen this month and one next month. Take it for what it's worth, I already know several will bash and also use their aliases to smear me. For the others:
(submissions to the FDA are not always public, companies choose to not let people down if the FDA denies it, until they are ready to let people down), both of these IND will be approved, there is no question based on unmet need.
-MANF approved for one ORPH IND end of SEPT (RP suspect)
-MANF approved for one ORPH IND end of OCT (Wolframs suspect)
-Lympro licensing partnership in Sept, diagnostic, not pharma, still just as huge if the diagnostic retains exclusivity in the US.
Just strong opinions from people far more in the know. Most of this makes sense and shouldn't be a huge surprise to anyone. Hopefully everyone's targets are hit and this can do what it was meant to do for people. Best of luck
PS, the Lympro aspect would make shares and RS unnecessary, by voting for both on your proxy, you're giving AMBS power to negotiate. Remember that the BOD and Gerald make these decisions, not just Gerald, so look at your BOD before slamming GC
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼